Convection-enhanced delivery to the central nervous system

Abbott, 2004, Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology, 45, 545, 10.1016/j.neuint.2003.11.006

Anderson, 2013, Convection-enhanced delivery of topotecan into diffuse intrinsic brainstem tumors in children, 11, 289, 10.3171/2012.10.PEDS12142

Asthagiri, 2011, Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer. Laboratory investigation, 115, 467, 10.3171/2011.3.JNS101381

Barua, 2013, Robot-guided convection-enhanced delivery of carboplatin for advanced brainstem glioma, 155, 1459, 10.1007/s00701-013-1700-6

Basser, 1992, Interstitial pressure, volume, and flow during infusion into brain tissue, 44, 143, 10.1016/0026-2862(92)90077-3

Blasberg, 1975, Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion, 195, 73

Bobo, 1994, Convection-enhanced delivery of macromolecules in the brain, 91, 2076, 10.1073/pnas.91.6.2076

Bogdahn, 2011, Targeted therapy for highgrade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study, 13, 132, 10.1093/neuonc/noq142

Bruce, 2000, Intracerebral clysis in a rat glioma model, 46, 683, 10.1097/00006123-200003000-00031

Bruce, 2011, Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan, 69, 1272, 10.1227/NEU.0b013e3182233e24

Carpentier, 2006, Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma, 8, 60, 10.1215/S1522851705000475

Carpentier, 2010, Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study, 12, 401, 10.1093/neuonc/nop047

Chen, 2005, Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system, 103, 311, 10.3171/jns.2005.103.2.0311

Chen, 1999, Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time, 90, 315, 10.3171/jns.1999.90.2.0315

Chen, 2013, Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts, 15, 189, 10.1093/neuonc/nos305

Chen, 2011, In vivo contrast-enhanced MR imaging of direct infusion into rat peripheral nerves, 39, 2823, 10.1007/s10439-011-0362-x

Chen, 2007, Biphasic finite element model of solute transport for direct infusion into nervous tissue, 35, 2145, 10.1007/s10439-007-9371-1

Chittiboina, 2014, Magnetic resonance imaging properties of convective delivery in diffuse intrinsic pontine gliomas. Clinical article, 13, 276, 10.3171/2013.11.PEDS136

Christine, 2009, Safety and tolerability of putaminal AADC gene therapy for Parkinson disease, 73, 1662, 10.1212/WNL.0b013e3181c29356

Ciesielska, 2011, Anterograde axonal transport of AAV2-GDNF in rat basal ganglia, 19, 922, 10.1038/mt.2010.248

Corem-Salkmon, 2011, Convection-enhanced delivery of methotrexate-loaded maghemite nanoparticles, 6, 1595

Croteau, 2005, Real-time in vivo imaging of the convective distribution of a low-molecular-weight tracer, 102, 90, 10.3171/jns.2005.102.1.0090

Crystal, 2004, Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis, 15, 1131, 10.1089/hum.2004.15.1131

Dickinson, 2008, Canine model of convectionenhanced delivery of liposomes containing CPT-11 monitored with real-time magnetic resonance imaging. Laboratory investigation, 108, 989, 10.3171/JNS/2008/108/5/0989

Ding, 2010, Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1, 98, 1, 10.1007/s11060-009-0046-7

Eberling, 2008, Results from a phase I safety trial of hAADC gene therapy for Parkinson disease, 70, 1980, 10.1212/01.wnl.0000312381.29287.ff

Fiandaca, 2009, Real-time MR imaging of adeno-associated viral vector delivery to the primate brain, 47, T27, 10.1016/j.neuroimage.2008.11.012

Gill, 2003, Direct brain infusion of glial cell linederived neurotrophic factor in Parkinson disease, 9, 589, 10.1038/nm850

Haar, 2010, Gd-DTPA T1 relaxivity in brain tissue obtained by convection-enhanced delivery, magnetic resonance imaging and emission spectroscopy, 55, 3451, 10.1088/0031-9155/55/12/012

Hdeib, 2011, Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas, 11, 799, 10.1517/14712598.2011.579097

Heiss, 2010, Image-guided convection-enhanced delivery of muscimol to the primate brain. Laboratory investigation, 112, 790, 10.3171/2009.7.JNS09652

Heiss, 2005, Local distribution and toxicity of prolonged hippocampal infusion of muscimol, 103, 1035, 10.3171/jns.2005.103.6.1035

Huynh, 2012, Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma, 423, 55, 10.1016/j.ijpharm.2011.04.037

Hwu, 2012, Gene therapy for aromatic L-amino acid decarboxylase deficiency, 4, 134ra161

Iyer, 2011, Tracking accuracy of T2- and diffusion-weighted magnetic resonance imaging for infusate distribution by convection-enhanced delivery. Laboratory investigation, 115, 474, 10.3171/2011.5.JNS11246

Jagannathan, 2008, Effect of ependymal and pial surfaces on convection-enhanced delivery. Laboratory investigation, 109, 547, 10.3171/JNS/2008/109/9/0547

Kaplitt, 2007, Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, 369, 2097, 10.1016/S0140-6736(07)60982-9

Kells, 2009, Efficient gene therapy-based method for the delivery of therapeutics to primate cortex, 106, 2407, 10.1073/pnas.0810682106

Kim, 2009, Voxelized model of interstitial transport in the rat spinal cord following direct infusion into white matter, 131, 071007, 10.1115/1.3169248

Kim, 2012, Voxelized computational model for convection-enhanced delivery in the rat ventral hippocampus: comparison with in vivo MR experimental studies, 40, 2043, 10.1007/s10439-012-0566-8

Krauze, 2005, Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. Technical note, 103, 923, 10.3171/jns.2005.103.5.0923

Ksendzovsky, 2012, Convection-enhanced delivery of M13 bacteriophage to the brain. Laboratory investigation, 117, 197, 10.3171/2012.4.JNS111528

Kunwar, 2010, Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma, 12, 871, 10.1093/neuonc/nop054

Kunwar, 2006, Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies, 20, E15

Kunwar, 2007, Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group, 25, 837, 10.1200/JCO.2006.08.1117

Lang, 2006, Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease, 59, 459, 10.1002/ana.20737

Langer, 1990, New methods of drug delivery, 249, 1527, 10.1126/science.2218494

Laske, 1997, Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging, 87, 586, 10.3171/jns.1997.87.4.0586

Laske, 1997, Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors, 3, 1362, 10.1038/nm1297-1362

Levy, 2001, Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms, 124, 2105, 10.1093/brain/124.10.2105

LeWitt, 2011, AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial, 10, 309, 10.1016/S1474-4422(11)70039-4

Lidar, 2004, Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study, 100, 472, 10.3171/jns.2004.100.3.0472

Lieberman, 1999, Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus, 90, 928, 10.3171/jns.1999.90.5.0928

Lieberman, 1995, Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion, 82, 1021, 10.3171/jns.1995.82.6.1021

Linninger, 2008, Computational methods for predicting drug transport in anisotropic and heterogeneous brain tissue, 41, 2176, 10.1016/j.jbiomech.2008.04.025

Linninger, 2008, Prediction of convection-enhanced drug delivery to the human brain, 250, 125, 10.1016/j.jtbi.2007.09.009

Lonser, 1999, Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates, 91, 294, 10.3171/jns.1999.91.2.0294

Lonser, 1998, Direct convective delivery of macromolecules to the spinal cord, 89, 616, 10.3171/jns.1998.89.4.0616

Lonser, 2007, Image-guided, direct convective delivery of glucocerebrosidase for neuronopathic Gaucher disease, 68, 254, 10.1212/01.wnl.0000247744.10990.e6

Lonser, 2002, Successful and safe perfusion of the primate brainstem: in vivo magnetic resonance imaging of macromolecular distribution during infusion, 97, 905, 10.3171/jns.2002.97.4.0905

Lonser, 2005, Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease, 57, 542, 10.1002/ana.20444

Lonser, 2007, Real-time image-guided direct convective perfusion of intrinsic brainstem lesions. Technical note, 107, 190, 10.3171/JNS-07/07/0190

Lonser, 1998, Direct convective delivery of macromolecules to peripheral nerves, 89, 610, 10.3171/jns.1998.89.4.0610

Marks, 2010, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, 9, 1164, 10.1016/S1474-4422(10)70254-4

Marks, 2008, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, 7, 400, 10.1016/S1474-4422(08)70065-6

Mittermeyer, 2012, Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease, 23, 377, 10.1089/hum.2011.220

Morrison, 2001, Distributed models of drug kinetics, 117

Morrison, 1999, Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics, 277, R1218

Morrison, 1994, High-flow microinfusion: tissue penetration and pharmacodynamics, 266, R292

Morrison, 2007, Convective delivery of glial cell line-derived neurotrophic factor in the human putamen, 107, 74, 10.3171/JNS-07/07/0074

Murad, 2006, Real-time, image-guided, convection-enhanced delivery of interleukin 13 bound to pseudomonas exotoxin, 12, 3145, 10.1158/1078-0432.CCR-05-2583

Murad, 2007, Image-guided convection-enhanced delivery of gemcitabine to the brainstem, 106, 351, 10.3171/jns.2007.106.2.351

Muramatsu, 2010, A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease, 18, 1731, 10.1038/mt.2010.135

Nduom, 2012, Comparison of pulsed versus continuous convective flow for central nervous system tissue perfusion. Laboratory investigation, 117, 1150, 10.3171/2012.9.JNS12506

Neeves, 2007, Dilation and degradation of the brain extracellular matrix enhances penetration of infused polymer nanoparticles, 1180, 121, 10.1016/j.brainres.2007.08.050

Nguyen, 2003, Convective distribution of macromolecules in the primate brain demonstrated using computerized tomography and magnetic resonance imaging, 98, 584, 10.3171/jns.2003.98.3.0584

Oh, 2007, Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter, 107, 568, 10.3171/JNS-07/09/0568

Oh, 2009, Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific liganddirected toxin, DTEGF13 and convection enhanced delivery, 95, 331, 10.1007/s11060-009-9932-2

Pahapill, 1999, Tremor arrest with thalamic microinjections of muscimol in patients with essential tremor, 46, 249, 10.1002/1531-8249(199908)46:2<249::AID-ANA15>3.0.CO;2-C

Pardridge, 1997, Drug delivery to the brain, 17, 713

Parney, 2005, Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma, 102, 267, 10.3171/jns.2005.102.2.0267

Patel, 2005, Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study, 57, 298, 10.1002/ana.20374

Patel, 2005, Safety and feasibility of convectionenhanced delivery of Cotara for the treatment of malignant glioma: initial experience in 51 patients, 56, 1243, 10.1227/01.NEU.0000159649.71890.30

Pöpperl, 2005, O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma, 32, 1018, 10.1007/s00259-005-1819-7

Raghavan, 2010, Fluid infusions from catheters into elastic tissue: I. Azimuthally symmetric backflow in homogeneous media, 55, 281, 10.1088/0031-9155/55/1/017

Rapoport, 1973, Osmotic opening of the bloodbrain barrier in the monkey without associated neurological deficits, 180, 971, 10.1126/science.180.4089.971

Ren, 2003, Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene—a phase I/II clinical protocol, 64, 147, 10.1007/BF02700029

Richardson, 2011, T2 imaging in monitoring of intraparenchymal real-time convection-enhanced delivery, 69, 154, 10.1227/NEU.0b013e318217217e

Rosenbluth, 2012, Analysis of a simulation algorithm for direct brain drug delivery, 59, 2423, 10.1016/j.neuroimage.2011.08.107

Rosenbluth, 2011, Design of an in-dwelling cannula for convection-enhanced delivery, 196, 118, 10.1016/j.jneumeth.2010.12.022

Rosenbluth, 2012, Evaluation of pressure-driven brain infusions in nonhuman primates by intra-operative 7 Tesla MRI, 36, 1339, 10.1002/jmri.23771

Saito, 2011, Regression of recurrent glioblastoma infiltrating the brainstem after convection-enhanced delivery of nimustine hydrochloride, 7, 522, 10.3171/2011.2.PEDS10407

Salegio, 2010, Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders, 21, 1093, 10.1089/hum.2010.040

Sampson, 2008, Intracerebral infusion of an EGFRtargeted toxin in recurrent malignant brain tumors, 10, 320, 10.1215/15228517-2008-012

Sampson, 2003, Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors, 65, 27

Sampson, 2010, Poor drug distribution as a possible explanation for the results of the PRECISE trial. Clinical article, 113, 301, 10.3171/2009.11.JNS091052

Sampson, 2011, Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans, 69, 668, 10.1227/NEU.0b013e3182181ba8

Sampson, 2007, Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin, 188, 703, 10.2214/AJR.06.0428

Sandberg, 2002, Convection-enhanced delivery into the rat brainstem, 96, 885, 10.3171/jns.2002.96.5.0885

Sarntinoranont, 2003, A computational model of direct interstitial infusion of macromolecules into the spinal cord, 31, 448, 10.1114/1.1558032

Sarntinoranont, 2006, Computational model of interstitial transport in the spinal cord using diffusion tensor imaging, 34, 1304, 10.1007/s10439-006-9135-3

Sarntinoranont, 2003, Direct interstitial infusion of NK1-targeted neurotoxin into the spinal cord: a computational model, 285, R243, 10.1152/ajpregu.00472.2002

Smith, 2011, A nonlinear biphasic model of flowcontrolled infusions in brain: mass transport analyses, 44, 524, 10.1016/j.jbiomech.2010.09.010

Souweidane, 2010, Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations, 6, 115, 10.3171/2010.4.PEDS09507

Strasser, 1995, Distribution of 1,3-bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants, 275, 1647

Szerlip, 2007, Real-time imaging of convection-enhanced delivery of viruses and virus-sized particles, 107, 560, 10.3171/JNS-07/09/0560

Tanner, 2007, Effects of drug efflux on convection-enhanced paclitaxel delivery to malignant gliomas: technical note, 61, E880, 10.1227/01.NEU.0000298922.77921.F2

Thorne, 2006, In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space, 103, 5567, 10.1073/pnas.0509425103

Vogelbaum, 2007, Convection-enhanced delivery of cintredekin besudotox (interleukin-13-PE38QQR) followed by radiation therapy with and without temozolomide in newly diagnosed malignant gliomas: phase 1 study of final safety results, 61, 1031, 10.1227/01.neu.0000303199.77370.9e

Voges, 2003, Imaging-guided convection-enhanced delivery and gene therapy of glioblastoma, 54, 479, 10.1002/ana.10688

Weaver, 2003, Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas, 65, 3, 10.1023/A:1026246500788

Weber, 2003, Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma, 64, 125, 10.1007/BF02700027

Weber, 2003, Local convection enhanced delivery of IL4-Pseudomonas exotoxin (NBI-3001) for treatment of patients with recurrent malignant glioma, 88, 93

White, 2011, An evaluation of the relationships between catheter design and tissue mechanics in achieving highflow convection-enhanced delivery, 199, 87, 10.1016/j.jneumeth.2011.04.027

White, 2012, A phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/ progressive glioblastoma multiforme, 33, 320, 10.1016/j.cct.2011.10.010

Wood, 1999, Convective delivery of macromolecules into the naive and traumatized spinal cords of rats, 90, 115

Worgall, 2008, Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA, 19, 463, 10.1089/hum.2008.022